Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Marker Therapeutics Inc (MRKR)
Marker Therapeutics Inc (MRKR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,800
  • Shares Outstanding, K 8,889
  • Annual Sales, $ 9,010 K
  • Annual Income, $ -29,930 K
  • 60-Month Beta 1.49
  • Price/Sales 5.88
  • Price/Cash Flow N/A
  • Price/Book 1.91
Trade MRKR with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 55.48%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.40 +8.53%
on 02/29/24
4.89 -24.54%
on 02/02/24
-0.95 (-20.39%)
since 02/01/24
3-Month
2.67 +38.20%
on 12/04/23
6.16 -40.07%
on 12/29/23
+0.93 (+33.70%)
since 12/01/23
52-Week
0.67 +450.25%
on 03/31/23
9.68 -61.88%
on 07/26/23
+1.64 (+80.00%)
since 03/01/23

Most Recent Stories

More News
Marker Therapeutics (NASDAQ: MRKR) Announces Leadership Transition and Strategic Partnership with CellReady to Strengthen Financial Position Through 2025

Houston-based Marker Therapeutics, Inc. (Nasdaq: MRKR) operates as a clinical-stage company focused on developing advanced T cell-based immunotherapies for hematological

MRKR : 3.69 (+1.65%)
Why Legend Biotech Stock Is Having Its Best Month Yet

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

LEGN : 65.53 (+0.57%)
JNJ : 162.12 (+0.46%)
BMY : 50.89 (+0.28%)
NVS : 102.06 (+1.08%)
BIIB : 220.95 (+1.82%)
ALNY : 152.61 (+1.01%)
MRKR : 3.69 (+1.65%)
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 38.46% and 393.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

MRKR : 3.69 (+1.65%)
ENTA : 15.35 (+6.82%)
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023...

MRKR : 3.69 (+1.65%)
Marker Therapeutics Reports Q1 2022 Operating and Financial Results

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year...

MRKR : 3.69 (+1.65%)
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

HOUSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the...

MRKR : 3.69 (+1.65%)
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Enrollment of first 20 patients of the Company’s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease...

MRKR : 3.69 (+1.65%)
Marker Therapeutics to Present at Two Upcoming March Investor Conferences

HOUSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the...

MRKR : 3.69 (+1.65%)
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

Results from safety lead-in stage of Marker’s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in...

MRKR : 3.69 (+1.65%)
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the...

MRKR : 3.69 (+1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T...

See More

Key Turning Points

3rd Resistance Point 3.93
2nd Resistance Point 3.84
1st Resistance Point 3.76
Last Price 3.69
1st Support Level 3.59
2nd Support Level 3.50
3rd Support Level 3.42

See More

52-Week High 9.68
Fibonacci 61.8% 6.24
Fibonacci 50% 5.18
Fibonacci 38.2% 4.11
Last Price 3.69
52-Week Low 0.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar